EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study

Hisashi Kosaka iD, Rie Sugimoto, Masahiko Kinoshita, Satoshi Yasuda, Satoru Kakizaki, Jun Sakata, Kiyonori Yamai, Takeshi Hatanaka, Yusuke Yamamoto, Toshifumi Sato, Toru Ishikawa, Takanori Morikawa und 14 weitere

Journal of Gastroenterology · 2026-08 · 61 (8) · 1170-1180

DOI: 10.1007/s00535-026-02412-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, online erschienen am 12.04.2026. Verfasst von Hisashi Kosaka und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1, Shin-machi, Hirakata, Osaka, 573-1010, Japan. kosaka.his@kmu.ac.jp. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Durvalumab plus gemcitabine–cisplatin (GCD) has become a standard first-line therapy for advanced biliary tract cancer (BTC) following the TOPAZ-1 trial. However, whether the survival benefit observed in trial-eligible patients can be generalized to broader real-world populations remains uncertain. We evaluated the impact of TOPAZ-1 eligibility on the effectiveness of GCD in routine clinical practice.

Methods

In this multicenter retrospective cohort study, 610 patients with unresectable or recurrent BTC treated with first-line GCD ( n = 268) or gemcitabine–cisplatin (GC) ( n = 342) at 19 Japanese institutions were analyzed. Patients were classified according to TOPAZ-1 eligibility criteria. Overall survival (OS) was compared between treatment groups in the entire cohort and stratified by eligibility status. Multivariable Cox models were constructed separately for eligible and ineligible patients.

Results

Among 610 patients, 324 (53.1%) met TOPAZ-1 eligibility criteria. In the overall cohort, GCD was associated with longer OS than GC (median, 13.7 vs 11.3 months; p = 0.009). Among eligible patients, GCD significantly improved OS compared with GC (18.0 vs 13.1 months; p = 0.004), whereas no significant difference was observed among ineligible patients (10.8 vs 10.0 months; p = 0.675). However, the interaction between treatment and TOPAZ-1 eligibility was not statistically significant ( p for interaction = 0.162).

Conclusions

In this real-world cohort, the survival benefit of GCD appeared to be primarily observed in patients meeting TOPAZ-1 eligibility criteria. Trial-based eligibility may influence the magnitude of benefit from immunochemotherapy in advanced BTC, underscoring the importance of patient selection in routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansGemcitabineDeoxycytidineFemaleCisplatinRetrospective StudiesAgedAntibodies, MonoclonalMaleMiddle AgedJapanTreatment OutcomePatient SelectionAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

Biliary tract neoplasmsCisplatinDurvalumabGemcitabineSurvival analysis

Substanzen

GemcitabineDeoxycytidineCisplatinAntibodies, Monoclonaldurvalumab

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1, Shin-machi, Hirakata, Osaka, 573-1010, Japan. kosaka.his@kmu.ac.jp.
  • Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center, Fukuoka, Japan.
  • Department of Hepatobiliary-Pancreatic Surgery, Osaka Metropolitan University, Osaka, Japan.
  • Department of Surgery, Nara Medical University, Kashihara, Japan.
  • Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
  • Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

ORCID-Profile: Hisashi Kosaka

Zitieren

APA

Kosaka, H., Sugimoto, R., Kinoshita, M., Yasuda, S., Kakizaki, S., Sakata, J., Yamai, K., Hatanaka, T., Yamamoto, Y., Sato, T., Ishikawa, T., Morikawa, T., Hanaoka, J., Mori, H., Toyoda, H., Sanuki, T., Yokoi, M., Shibata, H., Fukuda, K., …, & Kaibori, M. (2026). Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study. Journal of Gastroenterology, 61(8), 1170-1180. https://doi.org/10.1007/s00535-026-02412-6

Vancouver

Kosaka H, Sugimoto R, Kinoshita M, Yasuda S, Kakizaki S, Sakata J, et al. Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study. Journal of Gastroenterology. 2026;61(8):1170-1180. doi:10.1007/s00535-026-02412-6

BibTeX
@article{Kosaka2026,
  author = {Kosaka, Hisashi and Sugimoto, Rie and Kinoshita, Masahiko and Yasuda, Satoshi and Kakizaki, Satoru and Sakata, Jun and Yamai, Kiyonori and Hatanaka, Takeshi and Yamamoto, Yusuke and Sato, Toshifumi and Ishikawa, Toru and Morikawa, Takanori and Hanaoka, Jun and Mori, Haruki and Toyoda, Hidenori and Sanuki, Tsuyoshi and Yokoi, Misaki and Shibata, Hiroyuki and Fukuda, Koji and Kawata, Kazuhito and Amaya, Koji and Ito, Takashi and Hidaka, Masaaki and Naganuma, Atsushi and Sugimachi, Keishi and Kaibori, Masaki},
  title = {Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study},
  journal = {Journal of Gastroenterology},
  year = {2026},
  volume = {61},
  number = {8},
  pages = {1170--1180},
  doi = {10.1007/s00535-026-02412-6}
}
Kostenlos starten →